secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001104659-26-057140
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Q1 net loss $5M; FDA says single Phase 3 may suffice for QRX003
---------------------------------------------------------------------

- Net loss $5.0M in Q1 2026 vs $3.8M in Q1 2025; cash $14M expected to fund operations into 2027.
- FDA granted Fast Track Designation for QRX003 (Netherton Syndrome); Type C meeting indicated single Phase 3 may support U.S. approval.
- Phase 3 patient recruitment on track to complete by end of 2026; potential NDA filing in 2027.
- Japan MHLW confirmed QRX003 qualifies for Orphan Drug and Fast Track review; Saudi FDA Breakthrough Medicine Designation application filed.
- QRX009 topical rapamycin platform advancing; planned IND submission for additional indication by Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926057140/0001104659-26-057140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926057140/tm2613938d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-057140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer